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A popular area of medical research today is aimed at the development of markers for
classifying subjects as diseased or disease-free, high or low risk, or in terms of treatment
response or some other future event. These markers may be the results of, for example,
genetic or proteomic evaluations, imaging techniques, bacterial culture, or risk factor
information. Often times, there are other factors which aﬀect marker levels. For
example, prostate-speciﬁc antigen (PSA), a biomarker widely used to screen men for
prostate cancer, tends to increase with age. Many markers are also aﬀected by aspects
of the test procedure, test setting, or test operator; attributes of the specimen collection
or storage method (e.g., storage time); or “center eﬀects” in multi-center studies. While
adjustment for covariates is commonplace in therapeutic and etiologic studies, the issue
of covariate eﬀects is not well appreciated in the classiﬁcation setting. In this paper, we
demonstrate the need for covariate adjustment and describe statistical methods that
can be used to accomplish this. We also distinguish covariate adjustment from several
other closely related but fundamentally diﬀerent concepts, including matching, risk
score estimation, and incremental value. Finally, we provide practical recommendations
for determining when and how to adjust for covariates, and include links to software
that can be used to implement these techniques.
Why Adjust for Covariates?
The classiﬁcation accuracy of a continuous marker, Y , is its ability to distinguish
between two groups deﬁned by an outcome, which we loosely call ‘cases’ and ‘controls’.
Classiﬁcation accuracy is most commonly quantiﬁed using the ROC curve, a plot of
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the true positive fraction (TPF; sensitivity) versus the false positive fraction (FPF;
1 - speciﬁcity) for the set of rules which classify an individual as “test positive” if
their marker value is above a threshold, c, for all possible thresholds. The ROC curve
quantiﬁes the separation between the case and control marker distributions. It puts
markers on a common scale, thus facilitating comparing markers and comparing results
across studies. A sample ROC curve is shown in Figure 1.
Confounding occurs in evaluating classiﬁcation accuracy when there is a covariate
which is associated with both the marker and the binary outcome, D. In the presence
of such a covariate, the traditional pooled ROC curve, which combines all case obser-
vations together and all control observations together regardless of covariate value, is
biased. Consider the example shown in Figure 1, scenario 1 (reproduced from (1)). A
binary covariate (Z) is associated with both the outcome and the marker. For con-
creteness, suppose Z is an indicator of study center, where the proportion of cases
diﬀers between the two centers. Observe that the pooled ROC curve for Y is overopti-
mistic relative to the common covariate-speciﬁc ROC curve, since the center with the
most cases also tends to have higher marker levels. Failing to adjust for the covariate
(center) leads to an overoptimistic measure of marker performance.
But bias can occur even when the covariate is associated with the marker, but not
the binary outcome. Suppose that in the two-center study above the proportion of cases
is the same in the two centers. Observe in Figure 1, scenario 2 that the pooled ROC
curve for Y is now attenuated relative to the common covariate-speciﬁc ROC curve.
In this case, failing to adjust for the covariate leads to an underoptimistic measure of
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marker performance. This is directly analogous to studying the association between a
predictor and an outcome, in the presence of a covariate that is associated with the
predictor but independent of the outcome. The unadjusted odds ratio is attenuated
(2, 3). Unbiased estimation of the odds ratio for the predictor requires adjustment for
the covariate.
Observe in the scenarios depicted in Figure 1 that, when a covariate aﬀects the
distributions of the marker values but not the covariate-speciﬁc separation between
cases and controls, the separation seen in the pooled data is incorrect. Adjustment
for the covariate is necessary in order to appropriately compare the case and control
marker distributions. The covariate-adjusted ROC curve, written AROC, is a measure
of covariate-adjusted classiﬁcation accuracy (1). Conceptually, it is a stratiﬁed measure
of performance. When the performance of the marker is the same across covariate
groups (in other words, the covariate is not an eﬀect modiﬁer), the AROC is the
common covariate-speciﬁc ROC curve, which describes the performance of the marker
in a population with ﬁxed covariate value. See the solid ROC curve in Figure 1(b). It
is analogous to the adjusted odds ratio in an association study. Figure 2(a) shows the
age-adjusted ROC curve for PSA, estimated using data from the Physicians’ Health
Study (4). This ROC curve describes the ability of PSA to discriminate between
prostate cancer cases and controls of the same age.
Estimation of the simple ROC curve involves standardizing case marker observa-
tions with respect to the control reference distribution, and then calculating the cu-
mulative distribution function of these standardized marker values (5–7). Estimation
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of the AROC is identical except that case observations are standardized with respect
to the control distribution with the same covariate value as the case (1, 7). Addi-
tional details on estimating the AROC, including links to software, are included in the
appendix.
The Need to Adjust for Covariates When Comparing
Markers
In therapeutic studies with paired designs, the eﬀects of patient-speciﬁc characteristics
are controlled by measuring both predictors on the same subject. For example, in a
crossover trial of two drugs, a comparison of the responses under the two drugs does
not require adjustment by patient-level covariates because of the paired aspect of the
design. However, in evaluating classiﬁcation accuracy, we are not directly comparing
the markers; rather, we are comparing their ROC curves, or the separation between
the associated case and control distributions. Therefore, covariate adjustment is still
necessary. Consider the example shown in Figure 3, where Y1 and Y2 are two markers
measured on the same set of subjects. Suppose that Y1 and Y2 have the same inherent
performance (ROC curve), but Y1 is aﬀected by a binary covariate, Z, say study site,
while Y2 is not. Observe that the pooled ROC curves incorrectly indicate that Y2
outperforms Y1, since the ROC curve for Y1 is attenuated.
Markers can be compared with regard to covariate-adjusted classiﬁcation accuracy
using any of the commonly used ROC summary indices. For example, the area under
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the adjusted ROC curve (AAUC), the partial area under the adjusted ROC curve
(pAAUC), estimated sensitivity at a ﬁxed speciﬁcity, or estimated speciﬁcity at a ﬁxed
sensitivity can be used as summary measures. Links to software for estimating and
comparing these indices are provided in the appendix.
Why Matching is not Enough
Matching is a design technique which is commonly used when there are covariate eﬀects
on classiﬁcation accuracy. Cases are randomly sampled, and controls are matched to
the cases with respect to covariates known to be associated with the marker and the
outcome. Such matching is an attempt to control for confounding by these covariates,
as illustrated in Figure 1. For example, in the Physicians’ Health Study, controls were
matched to cases with respect to age in order to eliminate the contribution of age to
the apparent discriminatory accuracy of PSA (4). However, matching alone does not
solve the problem of confounding.
In etiologic studies, it has long been understood that matching does not eliminate
confounding. Odds ratios estimated from a matched study must be adjusted for the
matching covariates in the analysis (2, 3). Without adjustment, the odds ratios are
biased towards unity. The real role of matching is for eﬃciency gain in estimating these
odds ratios (2, 3).
Directly analogous results have been found in the classiﬁcation setting (8). That
is, matching does not eliminate the confounding. Rather, it converts the confounded
pooled ROC curve for the marker into an attenuated ROC curve. Consider the example
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shown in Figure 1 scenario 1, where Z (e.g., study center) is associated with both the
marker and the outcome. We observe that the unadjusted pooled ROC curve for the
marker is overoptimistic. A matched design forces Z to be independent of the outcome
in the data (i.e., the same proportion of cases in the two study centers), as in Figure
1 scenario 2. We see that the pooled ROC curve under such a design is still biased,
attenuated towards the 45◦ line. The covariate-adjusted ROC curve correctly estimates
the common covariate-speciﬁc ROC curve.
Figure 2(a) contrasts the age-adjusted ROC curve for PSA with the unadjusted
pooled ROC curve for PSA in the age-matched Physicians’ Health Study. Observe
that the unadjusted ROC curve in the matched data is generally lower than the age-
adjusted ROC curve, as it does not account for the matching.
As in etiologic studies, the real role for matching in studies of classiﬁcation accuracy
is for eﬃciency gain. Matching has been shown to be a maximally eﬃcient design in
many instances (8).
Other Uses for Covariates: Risk Score Estimation
and Incremental Value
Covariate adjustment is commonly confused with other uses for covariates in analyses
of classiﬁcation accuracy. We ﬁrst consider risk score estimation. The risk score is
the probability of the outcome (e.g., disease) as a function of marker and covariate
information (i.e., P [D = 1|Y, Z]). This function is commonly estimated using logistic
7
http://biostats.bepress.com/uwbiostat/paper310
regression where the outcome is regressed on one or more markers and other covariate
information,
log odds P [D = 1|Y, Z] = β0 + β1Y + β2Z.
We emphasize that the ROC curve for the risk score is diﬀerent from the covariate-
adjusted ROC curve for the marker. The ROC curve for the risk score describes
the ability of the combination of marker and covariates to discriminate between cases
and controls. Observe that this combination allows Z to contribute to discrimination.
Hence, the risk score may perform well even if Y is a poor classiﬁer, in particular if
Z discriminates well. Figure 4 (reproduced from (1)) displays two examples where the
ROC curve for the risk score is much higher than the AROC. In panel (a), Z is a
good classiﬁer but Y is not, and the two are relatively uncorrelated. The risk score
performs well, but the covariate-adjusted ROC curve for Y , i.e. the ROC curve for
Y stratiﬁed by Z, is low because it relates to the discriminatory accuracy of Y . In
panel (b), both Y and Z are good classiﬁers which are highly correlated. The risk
score performs well, as expected since it should be at least as good as either marker on
its own. However, after adjustment for Z the ROC curve for Y is low because within
a population where Z is ﬁxed, Y is not a good discriminator. Most of its marginal
discrimination is explained by Z, with which it is highly correlated.
Another concept commonly confused with covariate adjustment is incremental value.
The incremental value of the marker over the covariates is the amount of discrimina-
tory accuracy that the marker adds to the covariates. It is quantiﬁed by comparing the
ROC curve for the risk score, the optimal combination of marker and covariates (9), to
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the ROC curve for the covariates alone (10). Figure 5 (modiﬁed from (8)) shows two
examples which demonstrate that the covariate-adjusted performance of a marker is
diﬀerent from its incremental value. In panel (a), the incremental value of the marker
is large, but the covariate-adjusted ROC curve is low, and in panel (b), the incremental
value is small but the covariate-adjusted ROC curve is high. This interesting ﬁnding
represents another contrast between studies of association and studies of classiﬁcation.
In association studies, the contribution of one predictor over and above another is its
adjusted eﬀect on the outcome. In studies of classiﬁcation accuracy, these are two
diﬀerent constructs, once again a consequence of the fact that we are not adjusting for
the eﬀect of Z on the marker itself, but on the separation between the case and control
marker distributions (the ROC curve).
When Covariates Aﬀect Discrimination
Covariates which aﬀect the discriminatory accuracy of the marker (the ROC curve) are
analogous to eﬀect modiﬁers in the association setting. Common examples are severity
of disease and expertise of the test operator. With such covariates, a separate ROC
curve should be estimated for each covariate group. Covariate adjustment is often a
necessary ﬁrst step in estimating covariate-speciﬁc ROC curves, in order to adjust for
the eﬀects of the covariate on marker observations among controls. Figure 6 displays
a marker, Y , whose accuracy depends on a binary covariate, Z. For concreteness,
suppose again that Z is an indicator of study center. Now, however, diﬀerences in test
procedures between centers aﬀect marker performance (the separation between the case
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and control distributions) as well as the marker distributions. Observe that Y is much
more accurate when Z = 0 than when Z = 1. Marker observations among controls also
depend on Z (center), necessitating covariate adjustment, or standardization of case
marker observations relative to the appropriate covariate-speciﬁc control distribution.
Panel (b) shows the covariate-speciﬁc ROC curves for Y estimated with and without
adjustment for Z (center). Observe that the estimates of covariate-speciﬁc performance
are biased when Z is not adjusted. Case observations in the Z = 1 group are much
less unusual relative to the general (pooled) control marker distribution than they are
relative to the Z = 1 controls, leading to an attenuated ROC curve without adjustment
for Z. Case observations in the Z = 0 group are more unusual relative to the general
(pooled) control marker distribution than they are relative to the Z = 0 controls,
leading to an overoptimistic ROC curve without adjustment for Z.
The covariate-adjusted ROC curve is still useful when the covariate aﬀects discrim-
ination. It turns out that the AROC is a weighted average of the covariate-speciﬁc
ROC curves, with weights corresponding to the proportion of cases in each covariate
group (1). Observe in Figure 6(c) that the AROC for the marker lies in between the
two covariate-speciﬁc ROC curves. It can be interpreted as the average performance
of the marker across the two covariate groups. We see then that the AROC is directly
analogous to the Mantel-Haentzel adjusted odds ratio: it is the common covariate-
speciﬁc ROC curve when Z does not aﬀect discrimination, and a weighted average
more generally. It is useful in small studies when covariate-speciﬁc ROC curves cannot
be estimated with precision, and also provides a single summary of covariate-adjusted
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performance for comparing markers.
ROC regression methods can be used to test for whether or not covariates aﬀect
discrimination (6). In an ROC regression model, the parameters which describe the
eﬀect of Z on the ROC curve can be tested for statistical signiﬁcance. An ROC
regression model was ﬁt for PSA using Physicians’ Health Study data; the resulting
age-speciﬁc ROC curves are shown in Figure 2(b). Observe that there is essentially no
variation in discrimination across the age groups. The hypothesis test of the equivalence
of the ROC curves is not signiﬁcant (p = 0.98), implying that the AROC (also shown
in Figure 2(b)) is the common age-speciﬁc ROC curve for PSA.
Discussion and Practical Recommendations
Rigorous evaluation of new markers being developed for medical classiﬁcation purposes
is essential, and adjustment for covariates is an important component of this evalua-
tion. Adjustment is necessary for covariates that aﬀect marker observations among
controls. Failing to adjust for such covariates will lead to biased measures of marker
performance. Covariate adjustment is also essential for comparing markers, even un-
der a paired design, as unadjusted comparisons are biased in general. Neither does
matching eliminate the need for covariate adjustment; unadjusted measures of marker
performance in matched studies are generally attenuated.
The ﬁnal measure of covariate-adjusted classiﬁcation accuracy will depend on whether
the covariates also aﬀect discriminatory accuracy (are eﬀect modiﬁers). The AROC
and its associated summary indices are appropriate when the covariates do not af-
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fect discrimination, as well as in small studies and when comparing markers. If there
is heterogeneity in the accuracy of the marker across covariate groups, estimating
covariate-speciﬁc ROC curves should be the ultimate goal.
In practice, we suggest exploring associations between all measured covariates and
the marker among controls. If any associations are apparent, these covariates should
be used for adjustment. Alternatively, all measured covariates can be used for adjust-
ment, and the associated AROC compared with the pooled ROC to determine whether
adjustment makes any diﬀerence. In our experience, covariates must be very strongly
associated with the marker in order to cause appreciable bias in the pooled ROC curve.
A relatively minor concern is the potential for a loss of eﬃciency associated with
adjusting for covariates which are in fact independent of marker observations among
controls, but which appear to be associated in a given data set by random chance.
Interestingly, matching with respect to covariates prevents this loss of eﬃciency; the
pooled and covariate-adjusted ROC curves are equally eﬃcient under a matched design
(8).
Covariate adjustment is appropriate for covariates whose associations with the
marker and the outcome are considered, in some sense, a nuisance. Covariates which
are considered markers in their own right should be allowed to contribute to discrimi-
nation and should be combined with the marker in the risk score.
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Appendix
We have developed Stata programs for estimating, plotting, and comparing covariate-
adjusted ROC curves. These programs can be found at the Diagnostics and Biomarkers
Statistical Center (DABS) website, http://www.fhcrc.org/science/labs/pepe/dabs.
Estimation of the AROC involves standardizing case observations with respect to
the appropriate covariate-speciﬁc control distribution. A standardized case observation
is called its “placement value” (5–7, 11, 12). The cumulative distribution (CDF) of the
case placement values is the AROC. Hence, estimation of the AROC can be divided
into two steps: 1) calculate the placement values; 2) estimate their CDF.
In estimating the placement values, one must ﬁrst decide how to model the covari-
ates. Under existing approaches, this can be done by stratifying on the covariates or by
assuming that they act linearly on control marker observations. Next, one must decide
how to calculate the corresponding placement values, either empirically or assuming
a normal model for control marker observations. Finally, the CDF of the placement
values can be calculated empirically or based on the assumption of a binormal ROC
curve (13–16).
The AAUC and pAAUC can also be viewed as functions of case placement values
(11, 17). We estimate the AAUC as 1 minus the sample mean of the case placement
values, and the pAAUC as the sample mean of the “restricted” case placement values.
Another interesting summary measure is the estimated TPF at a ﬁxed FPF. Inference
about these AROC summary measures is accomplished using bootstrapping. Clustered
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Figure 1: A simulated marker Y and binary covariate Z = 0, 1. Under scenario 1, Z
is associated with the outcome: P [Z = 1|D = 0] = 0.10 and P [Z = 1|D = 1] = 0.50.
Under scenario 2, Z is independent of the outcome: P [Z = 1|D = 0] = P [Z =
1|D = 1] = 0.50. (a) The densities of Y conditional on Z = 0, conditional on Z = 1,
in the pooled data under scenario 1, and in the pooled data under scenario 2. A
common threshold of 2.5 is indicated. (b) The common covariate-speciﬁc ROC curve,
the pooled ROC curve under scenario 1, and the pooled ROC curve under scenario 2.
The performances of the thresholding rule are indicated.
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Figure 2: ROC curves for PSA in the PHS data. (a) The age-adjusted ROC curve





















Figure 3: Two simulated markers Y1 and Y2 which have the same performance. Y1
depends on a binary covariate Z = 0, 1, while Y2 does not. The binary outcome does
not depend on the covariate. (a) The densities of Y1 conditional on Z = 0, conditional
on Z = 1, and in the pooled data. A common threshold of 2.5 is indicated. (b) The
densities of Y2 conditional on Z = 0, conditional on Z = 1, and in the pooled data. (c)
The common covariate-speciﬁc ROC curve for Y1 and Y2, the pooled ROC curve for
Y1, and the pooled ROC curve for Y2. The performances of the thresholding rule are
indicated.




−4 0 4 8
Z = 1


























Hosted by The Berkeley Electronic Press
Figure 4: Two simulated examples to illustrate that the ROC curve for the risk score,
R = P [D = 1|Y, Z], is diﬀerent from the common covariate-speciﬁc ROC curve. The
ROC curve for R and the common covariate-speciﬁc ROC curve are shown. (a) Z is a
good classiﬁer but Y is not, and the two are relatively uncorrelated. (b) Both Y and


















Figure 5: Two simulated examples, illustrating that the covariate-adjusted ROC curve
is not related to the incremental value. In each example, the covariate-adjusted ROC
curve is shown, along with the ROC curves for the risk score, R = P [D = 1|Y, Z], and
for Z alone. (a) The incremental value is large, and the covariate-adjusted ROC curve
is low. (b) The incremental value is small, and the covariate-adjusted ROC curve is
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Figure 6: A simulated marker Y and binary covariate Z = 0, 1. The performance of Y
depends on Z, but Z is independent of the outcome. (a) The densities of Y conditional
on Z = 0, conditional on Z = 1, and in the pooled data. A common threshold of 2.5 is
indicated. (b) The covariate-speciﬁc ROC curves for Y with and without adjustment
for Z. The performances of the threshold are indicated. (c) The covariate-speciﬁc and
covariate-adjusted ROCs curves for Y .
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